Organix, Inc., part of Symeres BV, is a company headquartered in Woburn, MA. The firm provides organic synthesis services. It was founded in 1986 by Raj K. Razdan, Howard Sard and Peter Meltzer. Anu Mahadevan is the CEO, in this role since 1997. Symeres BV acquired Organix, Inc. on April 26, 2022.\nThe company says this about itself: Organix is a Contract Research Organization (CRO) founded in 1986, based in Woburn (US) just outside of Boston. It is a fast-growing company with c.45 employees that serves scientists in biopharma firms all over the world, providing high-quality organic chemistry services, primarily in the areas of lipids and small molecules. The company is owned and led by Dr. Anu Mahadevan, CEO and Dr. Paul Blundell, President.

Nanopharm Ltd. engages in the provision of orally inhaled and nasal drug product design and development services. It offers pre-formulation, formulation, and analytical solutions. The company was founded by Robert Price and is headquartered in Newport, the United Kingdom.

Esteve Pharmaceuticals S.A. operates as a global pharmaceutical company. It provides Ophthalmology and other Pathologies therapies. The company is headquartered in Barcelona, Spain.

nLife Therapeutics, S.L., a Granada, Spain-based company that develops innovative tratments for CNS diseases. The company intends to use the funds to advance clinical trials for its treatments. nLife Therapeutics is working on next generation targeted nucleic acids products. Its technology delivers conjugated nucleic acids with small chemicals to selected neurons after a single intra-nasal application.

Alla Chem LLC is a company headquartered in Hallandale Beach, FL, involved in pharmaceutical preparations. It was founded in 2004.

Adolor Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pain and pain-management products. ENTEREG (alvimopan) is the United States Food and Drug Administration (FDA) approved product. ENTEREG is indicated to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. The Company is conducting two Phase 2 clinical trials of ADL5945 to treat opioid-induced constipation (OIC), a condition that often results from long-term use of opioid analgesics in the management of chronic pain conditions. In addition, it is continuing development efforts on ADL7445, a second peripherally-acting mu opioid receptor antagonist, which is considered a back-up compound in its OIC program. The Company has completed Phase 1 clinical evaluation of ADL6906 (beloxepin).

Afecta Pharmaceuticals, Inc. is an American private company located in Irvine, CA, focused on pharmaceutical preparations.

Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA.

Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers.\nThey have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas.\nIts objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization.\nBesipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development.\nDevelopment is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC.

Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the Central Nervous System (CNS). We combine the efforts of medicinal chemists, pharmacologists, biologists and clinical development scientists into a vibrant team that translates world-class research expertise into novel drugs. The company's lead product, ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (DPPM) designed to treat multiple deficits in patients with schizophrenia while lacking the side-effects of existing antipsychotic drugs. ITI has also developed a state of the art technology platform, called CNSProfile™ that is capable of generating a unique molecular signature for drug compounds. This profile provides us with a proprietary window into the intracellular action of CNS drugs or drug candidates. We use this tool to fingerprint the intracellular molecular actions of existing drugs and to drive our internal drug discovery and development. Our technology has also enabled the company to examine the toxic effects of brain damaging nerve agents, and as a result, we are involved in collaborative efforts with several military and contract organizations to develop antidotes to chemical warfare agents. Based upon our understanding of the Central Nervous System we have discovered novel drug candidates with promise for treating the panoply of symptoms associated with the transition from peri-menopausal to post-menopausal states. Intra-Cellular Therapies was founded in 2002 by Drs. Paul Greengard, Sharon Mates and Allen Fienberg. The company is headquartered in New York City.

Xenome is a progressive Australian biotechnology company with a promising and distinctive technology platform targeting pain and inflammation. Xen2174, the Company's lead drug candidate is currently completing a Phase 1b/2a clinical trial for cancer pain with evidence to date providing strong support that the trial endpoints will be successfully met. More substantive clinical trials for expanded indications are planned for 2008. In addition, the drug discovery platform from which Xen2174 emerged has inherent value due to its ability to repeatedly identify new lead medicinal compounds on the basis of its unique construction around Australian biodiversity. Specifically, Xenome has generated a unique expertise in peptide chemistry to translate the evolutionary advantages inherent in venom peptides into highly bioactive libraries of molecules that are of interest to global biotechnology and pharmaceutical companies.

Zevra Therapeutics is a development-stage biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. The company’s primary efforts include the development of safer, abuse-resistant opioid pain relievers. Its drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. KemPharm uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.

NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON.

Sanofi A/S engages in the production of prescription drugs as well as participates in clinical trials of present and future products. It specializes in diabetes, oncology, multiple sclerosis, rare disease and cardio vascular illnesses. The company is headquartered in Copenhagen, Denmark.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Shanghai Guolian Stem Cell Technology Co., Ltd., established on 2009-12-17, Business scope includes stem cell biotechnology(Except for special items)technology development,technical consulting,Technical Services,technology transfer. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]